ClinicalTrials.gg
CompletedNCT06384755HOP-NORUpdated Nov 20, 2026

Honest Open Proud for Psychotic and Bipolar Disorder in Norway

An interventional study of Honest Open Proud program in Psychotic Disorders, Bipolar Disorder and Disclosure, sponsored by Oslo University Hospital. Completed at 2 sites in Norway. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Oslo University Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Nov 20, 2026Now CompletedPrimary completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Psychotic Disorders with a site in Norway — 6 open to participants now, 7 under way, none of them phase 3. Psychotic Disorders · Norway.

Enrollment
16th of 20
40 · median 87
Started
2024
with 2 others
No phase
12 of 26
5 open now
Registered
23rd of 26
by date
Lead sponsor
7 of 26
Oslo University Hospital

Among the 26 studies in Psychotic Disorders with a site in Norway, this one is the 16th largest by enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2024, is one of 12 with no phase, and was the 23rd registered.

Psychotic Disorders

1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

6 of the 26 studies in Psychotic Disorders with a site in Norway are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Psychotic Disorders with a site in Norway, or all of them as a file.
02

Study summary

The purpose of this pilot study is to evaluate the feasibility, acceptability and efficacy of a Norwegian adaptation of the group-based intervention 'Honest Open Proud' among adults with psychotic and bipolar disorders in an outpatient setting.

Read the detailed description

Because people with mental illness experience both public and personal stigma, which is related to lower levels of recovery and wellbeing, it is common to struggle with decisions regarding potential disclosure of mental health difficulties or diagnoses. There are pros and cons with both disclosure and secrecy. Disclosure can lead to social support, followed by improved mental health and reduced public stigma, but also stigmatization and social exclusion. Secrecy can prevent stigmatization but may also lead to social isolation and thus poorer mental health and increased public stigma. Therefore, people with mental illness need help to make strategic decisions about whether, and if so, to whom, when and how they wish to disclose their mental health problems. As contact with other people with mental health difficulties is crucial to anti-stigma interventions, people with mental illness could benefit from meeting peers, especially as role models. This suggests that peer facilitators could be an important feature in a program aiming to help people with mental illness handle stigma and challenges related to disclosure. The Honest Open Proud (HOP) program was developed for this purpose. Because people with psychotic and bipolar disorders experience particularly high levels of both public and personal stigma, which negatively impacts their recovery rates, they may be especially in need of the HOP program.

The investigators aim to evaluate whether a Norwegian adaptation of the HOP group program, which is facilitated by peers, is feasible and acceptable for people with psychotic and bipolar disorders in an outpatient setting. Moreover, whether it helps them handle stigma and disclosure related decisions.

The investigators propose a pilot randomized controlled trial, comparing an intervention group receiving a 6-week Norwegian adaptation of the HOP program to a waiting list control group. Both groups receive treatment as usual. The main research question is whether this intervention is feasible and acceptable. However, efficacy measures tapping change in stigma and disclosure distress, as well as recovery and wellbeing, from before to after the intervention, were included. The aim is to find what effect sizes can be expected in future larger studies in Norway, rather than to find significant differences in effect sizes. We also added a descriptive follow-up 6-24 months (depending on cohort) after the intervention.

03

Conditions studied

  • Psychotic Disorders
  • Bipolar Disorder
  • Disclosure

Keywords

  • Honest Open Proud program
  • Psychotic and Bipolar disorders
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed current psychotic (F 20) or bipolar disorder (F 30) according to International Classification of Diseases 10th Revision (ICD-10)
  • Age 18 to 65
  • Ability to provide written .
  • Fluent in Norwegian (needed for self-report measures)
  • Experience difficulties with stigma and disclosure regarding mental illness.

Exclusion criteria

Exclusion Criteria:

  • Intellectual disability
  • Organic disorders
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Intervention group

    Intervention group: receives the HOP program consisting of four 2-hour sessions divided between week 1, week 2, week 3 and week 6, in groups of 4-10 participants, using a Norwegian adaptation of HOP workbook. The intervention group also receives treatment as usual, consisting of weekly or monthly appointments with a mental health care professional at an outpatient unit in the public mental health care service. The appointments can involve medication management, psychoeducation, support therapy or psychotherapy.

    Behavioral: Honest Open Proud program

  • No intervention
    Waiting list control group

    Waiting list control group: receives only treatment as usual, consisting of weekly or monthly appointments with a mental health care professional at an outpatient unit in the public mental health care service. The appointments can involve medication management, psychoeducation, support therapy or psychotherapy. They are offered the HOP program after the trial.

Interventions

  • BehavioralHonest Open Proud program

    The HOP program involves peer facilitated sessions, in which different stigma and disclosure related topics are introduced to the group, relevant tasks are completed individually, followed by group or two-and-two discussions related to the following topics: week 1 = pros and cons with disclosure, week 2 = different ways of disclosing, week 3 = formulating individual decisions of disclosure, week 6 = evaluating disclosure or non-disclosure in practice.

    Also known as: Coming Out Proud (COP)

06

What researchers measure

Primary outcomes

  1. Stigma Stress Scale (Rüsch, Corrigan, Wassel et al., 2009; Rüsch, Corrigan, Powell et al., 2009)

    8 items, from 1 (strongly disagree) to 7 (strongly agree)

    Time frame: Change from T0 to T1 and T2 (assessed at T0 = week 0; T1 =week 3; T2 = week 6) A descriptive follow-up from T2 to T3 (assessed at 6-24 months after intervention depending on cohort) was added after completion of all four cohorts

Secondary outcomes

  1. Disclosure Distress (Rüsch et al., 2014a)

    1 item "In general, how distressed or worried are you in terms of secrecy or disclosure of your mental illness to others?", from 1 (not at all) to 7 (very much)

    Time frame: Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) A descriptive follow-up from T2 to T3 (assessed at 6-24 months after intervention depending on cohort) was added after completion of all four cohorts

  2. Warwick and Edinburgh Wellbeing Scale (WEMWBS) (Tennant et al 2007)

    14-items, from 1 (not at all) to 5 (all the time)

    Time frame: Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) A descriptive follow-up from T2 to T3 (assessed at 6-24 months after intervention depending on cohort) was added after completion of all four cohorts

  3. Satisfaction with life (Lehman, 1988)

    1 item from Lehmans Quality of Life Scale, from 1 (very dissatisfied) to 7 (very satisfied)

    Time frame: Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) A descriptive follow-up from T2 to T3 (assessed at 6-24 months after intervention depending on cohort) was added after completion of all four cohorts

  4. The Questionnaire about the Process of Recovery - 15 (QPR-15) (Niel et al 2007)

    15 items short version, from 0 (strongly disagree) to 4 (strongly agree)

    Time frame: Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) A descriptive follow-up from T2 to T3 (assessed at 6-24 months after intervention depending on cohort) was added after completion of all four cohorts

  5. Internalised Stigma of Mental Illness Inventory (ISMI-10) (Boyd, Otilingam, & Deforge, 2014)

    10-item short version, from 1 (strongly disagree ) to 4 (strongly agree )

    Time frame: Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) A descriptive follow-up from T2 to T3 (assessed at 6-24 months after intervention depending on cohort) was added after completion of all four cohorts

  6. Patient Health Questionnaire-4 (PHQ-9) (Kroenke et al 2009)

    9 items, 0 (not at all) to 3 (nearly every day)

    Time frame: Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) A descriptive follow-up from T2 to T3 (assessed at 6-24 months after intervention depending on cohort) was added after completion of all four cohorts

  7. Generalized Anxiety disorder (GAD-7) (Spitzer et al, 2006)

    7 items, from 0 (not at all) to 3 (nearly every day)

    Time frame: Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) A descriptive follow-up from T2 to T3 (assessed at 6-24 months after intervention depending on cohort) was added after completion of all four cohorts

Other outcomes

  1. Disclosure

    "Have you disclosed your mental illness the last three (or six) weeks?", YES/NO "How satisfied are you with that?", from 1 (very dissatisfied) to 7 (very satisfied)

    Time frame: Assessed at T1 and T2 (T1= week 3 and T2 = week 6) This question was also included at T3 (last six weeks)

  2. Feasibility of HOP program

    Recruitment rates (numbers of participants in number of weeks) and drop-out rates.

    Time frame: Tracked during trial and evaluated after completion (T2 = week 6)

  3. Acceptability of HOP program participants

    Semi-structured focus-group interview about acceptability with HOP program participants

    Time frame: Assessed after T2 = week 6

  4. Acceptability of HOP peer facilitators

    Semi-structured focus-group interview about acceptability with HOP peer facilitators

    Time frame: Assessed after T2 = week 6

07

Study locations

2 sites
  • Nydalen DPS, Division of Mental Health and Addiction, Oslo University Hospital
    Oslo, Oslo 0351, Norway
  • Søndre Oslo DPS, Division of Mental Health and Addiction, Oslo University Hospital
    Oslo, Oslo 1281, Norway
08

References and documents

Individual participant data

Plan to share: No — The study protocol can be shared, but not the the actual data.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Oct 2026, 30 months.

Of 460 non-industry interventional studies with no phase under Psychotic Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's 30 months is below that.

Counting every sponsor, half of 462 studies reached it within 34 months; a quarter within 19 and three quarters within 52.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Dec 2024 → Oct 2026 and completion Dec 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2024
First posted
Apr 25, 2024
StartActual
Apr 20, 2024
Primary completionActual
Oct 30, 2026was Dec 2024
CompletionActual
Oct 30, 2026was Dec 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 20, 2026
Sites
2 sites added, 2 sites removed
Show 2 added (2 Norway)
  • Nydalen DPS, Division of Mental Health and Addiction, Oslo University Hospital · Oslo, Norway
  • Søndre Oslo DPS, Division of Mental Health and Addiction, Oslo University Hospital · Oslo, Norway
Show 2 removed
  • Nydalen DPS, Division of Mental Health and Addiction, Oslo University Hospital · Oslo, Norway
  • Søndre Oslo DPS, Division of Mental Health and Addiction, Oslo University Hospital · Oslo, Norway
Nov 20, 2026
Primary completion
Dec 31, 2024→Oct 30, 2026 (actual)
Nov 20, 2026
Study completion
Dec 31, 2026→Oct 30, 2026 (actual)
Nov 20, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameStigma Stress Scale (Rüsch, Corrigan, Wassel et al., 2009; Rüsch, Corrigan, Powell et al., 2009)Change from T0 to T1 and T2 (assessed at T0 = week 0; T1 =week 3; T2 = week 6) → Change from T0 to T1 and T2 (assessed at T0 = week 0; T1 =week 3; T2 = week 6) A descriptive follow-up from T2 to T3 (assessed at 6-24 months after intervention depending on cohort) was added after completion of all four cohorts
Nov 20, 2026
Secondary outcomes
8 time frame changed
What changed in the outcomes
  • Time frameDisclosure Distress (Rüsch et al., 2014a)Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) → Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) A descriptive follow-up from T2 to T3 (assessed at 6-24 months after intervention depending on cohort) was added after completion of all four cohorts
  • Time frameWarwick and Edinburgh Wellbeing Scale (WEMWBS) (Tennant et al 2007)Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) → Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) A descriptive follow-up from T2 to T3 (assessed at 6-24 months after intervention depending on cohort) was added after completion of all four cohorts
  • Time frameSatisfaction with life (Lehman, 1988)Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) → Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) A descriptive follow-up from T2 to T3 (assessed at 6-24 months after intervention depending on cohort) was added after completion of all four cohorts
  • Time frameThe Questionnaire about the Process of Recovery - 15 (QPR-15) (Niel et al 2007)Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) → Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) A descriptive follow-up from T2 to T3 (assessed at 6-24 months after intervention depending on cohort) was added after completion of all four cohorts
  • Time frameInternalised Stigma of Mental Illness Inventory (ISMI-10) (Boyd, Otilingam, & Deforge, 2014)Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) → Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) A descriptive follow-up from T2 to T3 (assessed at 6-24 months after intervention depending on cohort) was added after completion of all four cohorts
  • Time framePatient Health Questionnaire-4 (PHQ-9) (Kroenke et al 2009)Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) → Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) A descriptive follow-up from T2 to T3 (assessed at 6-24 months after intervention depending on cohort) was added after completion of all four cohorts
  • Time frameGeneralized Anxiety disorder (GAD-7) (Spitzer et al, 2006)Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) → Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) A descriptive follow-up from T2 to T3 (assessed at 6-24 months after intervention depending on cohort) was added after completion of all four cohorts
  • Time frameother outcomeDisclosureAssessed at T1 and T2 (T1= week 3 and T2 = week 6) → Assessed at T1 and T2 (T1= week 3 and T2 = week 6) This question was also included at T3 (last six weeks)
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Recruiting→Completed
    2 sites added, 2 sites removed
    Show 2 added (2 Norway)
    • Nydalen DPS, Division of Mental Health and Addiction, Oslo University Hospital · Oslo, Norway
    • Søndre Oslo DPS, Division of Mental Health and Addiction, Oslo University Hospital · Oslo, Norway
    Show 2 removed
    • Nydalen DPS, Division of Mental Health and Addiction, Oslo University Hospital · Oslo, Norway
    • Søndre Oslo DPS, Division of Mental Health and Addiction, Oslo University Hospital · Oslo, Norway
    Primary completion Dec 31, 2024→Oct 30, 2026 (now actual)
    Study completion Dec 31, 2026→Oct 30, 2026 (now actual)
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameStigma Stress Scale (Rüsch, Corrigan, Wassel et al., 2009; Rüsch, Corrigan, Powell et al., 2009)Change from T0 to T1 and T2 (assessed at T0 = week 0; T1 =week 3; T2 = week 6) → Change from T0 to T1 and T2 (assessed at T0 = week 0; T1 =week 3; T2 = week 6) A descriptive follow-up from T2 to T3 (assessed at 6-24 months after intervention depending on cohort) was added after completion of all four cohorts
    Secondary outcomes 8 time frame changed
    What changed in the outcomes
    • Time frameDisclosure Distress (Rüsch et al., 2014a)Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) → Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) A descriptive follow-up from T2 to T3 (assessed at 6-24 months after intervention depending on cohort) was added after completion of all four cohorts
    • Time frameWarwick and Edinburgh Wellbeing Scale (WEMWBS) (Tennant et al 2007)Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) → Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) A descriptive follow-up from T2 to T3 (assessed at 6-24 months after intervention depending on cohort) was added after completion of all four cohorts
    • Time frameSatisfaction with life (Lehman, 1988)Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) → Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) A descriptive follow-up from T2 to T3 (assessed at 6-24 months after intervention depending on cohort) was added after completion of all four cohorts
    • Time frameThe Questionnaire about the Process of Recovery - 15 (QPR-15) (Niel et al 2007)Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) → Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) A descriptive follow-up from T2 to T3 (assessed at 6-24 months after intervention depending on cohort) was added after completion of all four cohorts
    • Time frameInternalised Stigma of Mental Illness Inventory (ISMI-10) (Boyd, Otilingam, & Deforge, 2014)Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) → Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) A descriptive follow-up from T2 to T3 (assessed at 6-24 months after intervention depending on cohort) was added after completion of all four cohorts
    • Time framePatient Health Questionnaire-4 (PHQ-9) (Kroenke et al 2009)Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) → Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) A descriptive follow-up from T2 to T3 (assessed at 6-24 months after intervention depending on cohort) was added after completion of all four cohorts
    • Time frameGeneralized Anxiety disorder (GAD-7) (Spitzer et al, 2006)Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) → Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6) A descriptive follow-up from T2 to T3 (assessed at 6-24 months after intervention depending on cohort) was added after completion of all four cohorts
    • Time frameother outcomeDisclosureAssessed at T1 and T2 (T1= week 3 and T2 = week 6) → Assessed at T1 and T2 (T1= week 3 and T2 = week 6) This question was also included at T3 (last six weeks)
    + 4 other changes: verification date, responsible party, description and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06384755
Collaborators
University of Oslo
Responsible party
Carmen Simonsen (Professor, Oslo University Hospital) — Principal investigator
First posted
Apr 25, 2024
Start date
Apr 20, 2024
Primary completion
Oct 30, 2026
Completion
Oct 30, 2026
Last update
Nov 20, 2026

Study contacts

Carmen Simonsen, PhD
principal investigator · Department of Psychology, University of Oslo

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion